Using pdx for preclinical cancer drug discovery: The evolving field

Journal of Clinical Medicine

Volumn 7, Issue 3, 2018, Pages

  Williams, Juliet A ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Avatars; Drug discovery; Humanized mouse models; Mouse clinical trials (MCT); Patient derived xenograft

Indexed keywords

ANTIBODY DRUG CONJUGATE; RETINOBLASTOMA PROTEIN;

CHROMOSOME NUMBER; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DRUG SCREENING; HISTOPATHOLOGY; MOUSE; NONHUMAN; REVIEW; SCREENING TEST; XENOGRAFT;

EID: 85052848010     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm7030041     Document Type: Review

References (99)

1. Gao, H.; Korn, J.M.; Ferretti, S.; Monahan, J.E.; Wang, Y.; Singh, M.; Zhang, C.; Schnell, C.; Yang, G.; Zhang, Y.; et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 2015, 21, 1318–1325. [CrossRef] [PubMed]
2. Woglom, W.H. The Study of Experimental Cancer: A Review; Columbia University Press: New York, NY, USA, 1913; Volume 1.
3. Murphy, J.B. Transplantability of malignant tumors to the embryos of a foreign species. J. Am. Med. Assoc. 1912, LIX, 874–875. [CrossRef]
4. Toolan, H.W. Transplantable human neoplasms maintained in cortisone-treated laboratory animals: H.S. No. 1; H.Ep. No. 1; H.Ep. No. 2; H.Ep. No. 3; and H.Emb.Rh. No. 1. Cancer Res. 1954, 14, 660–666. [PubMed]
5. Isaacson, J.H.; Cattanach, B.M. Report. Mouse News Lett. 1962, 27, 31.
6. Pantelouris, E.M. Absence of thymus in a mouse mutant. Nature 1968, 217, 370–371. [CrossRef] [PubMed]
7. Bosma, G.C.; Custer, R.P.; Bosma, M.J. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301, 527–530. [CrossRef] [PubMed]
8. Shultz, L.D.; Schweitzer, P.A.; Christianson, S.W.; Gott, B.; Schweitzer, I.B.; Tennent, B.; McKenna, S.; Mobraaten, L.; Rajan, T.V.; Greiner, D.L.; et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 1995, 154, 180–191. [PubMed]
9. Cao, X.; Shores, E.W.; Hu-Li, J.; Anver, M.R.; Kelsall, B.L.; Russell, S.M.; Drago, J.; Noguchi, M.; Grinberg, A.; Bloom, E.T.; et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2, 223–238. [CrossRef]
10. Townsend, E.C.; Murakamii, M.; Christodoulou, A.; Christie, A.L.; Köster, J.; DeSouza, T.A.; Morgan, E.A.; Kallgren, S.P.; Liu, H.; Wu, S.C.; et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell 2016, 29, 574–586. [CrossRef] [PubMed]
11. Byrne, A.T.; Alférez, D.G.; Amant, F.; Annibali, D.; Arribas, J.; Biankin, A.V.; Bruna, A.; Budinská, E.; Caldas, C.; Chang, D.K.; et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 2017, 17, 254–268. [CrossRef] [PubMed]
12. Stewart, E.; Federico, S.M.; Chen, X.; Shelat, A.A.; Bradley, C.; Gordon, B.; Karlstrom, A.; Twarog, N.R.; Clay, M.R.; Bahrami, A.; et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 2017, 549, 96–100. [CrossRef] [PubMed]
13. Murakami, M.A.; Weinstock, D.M. The next best thing. Nature 2017, 549, 39–41. [CrossRef] [PubMed]
14. Kaiser, J. Major funders launch international repository of cutting-edge cancer models. Science 2016. [CrossRef]
15. Bruna, A.; Rueda, O.M.; Greenwood, W.; Batra, A.S.; Callari, M.; Batra, R.N.; Pogrebniak, K.; Sandoval, J.; Cassidy, J.W.; Tufegdzic-Vidakovic, A.; et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 2016, 167, 260–274. [CrossRef] [PubMed]
16. Hidalgo, M.; Amant, F.; Biankin, A.V.; Budinska, E.; Byrne, A.T.; Caldas, C.; Clarke, R.B.; de Jong, S.; Jonkers, J.; Mælandsmo, G.M.; et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014, 4, 998–1013. [CrossRef] [PubMed]
17. Whittle, J.R.; Lewis, M.T.; Lindeman, G.J.; Visvader, J.E. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015, 17, 17–20. [CrossRef] [PubMed]
18. Toivanen, R.; Berman, D.M.; Wang, H.; Pedersen, J.; Frydenberg, M.; Meeker, A.K.; Ellem, S.; Risbridger, G.P.; Taylor, R.A. Brief report: A bioassay to identify primary human prostate cancer repopulating cells. Stem Cells 2011, 29, 1310–1314. [CrossRef] [PubMed]
19. Van Weerden, W.M.; Romijn, J.C. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000, 43, 263–271. [CrossRef]
20. Wang, Y.; Revelo, M.; Sudilovsky, D.; Cao, M.; Chen, W.; Goetz, L.; Xue, H.; Sadar, M.; Shappell, S.B.; Cunha, G.R.; et al. Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate 2005, 64, 149–159. [CrossRef] [PubMed]
21. Gray, D.R.; Huss, W.J.; Yau, J.M.; Durham, L.E.; Werdin, E.S.; Funkhouser, W.K., Jr.; Smith, G. Short-term human prostate primary xenografts: An in vivo model of human prostate cancer vasculature and angiogenesis. Cancer Res. 2004, 64, 1712–1721. [CrossRef] [PubMed]
22. Alsop, K.; Thorne, H.; Sandhu, S.; Hamilton, A.; Mintoff, C.; Christie, E.; Spruyt, O.; Williams, S.; McNally, O.; Mileshkin, L.; et al. A community-based model of rapid autopsy in end-stage cancer patients. Nat. Biotechnol. 2016, 34, 1010–1014. [CrossRef] [PubMed]
23. Juric, D.; Castel, P.; Griffith, M.; Griffith, O.L.; Won, H.H.; Ellis, H.; Ebbesen, S.H.; Ainscough, B.J.; Ramu, A.; Iyer, G.; et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor. Nature 2015, 518, 240–244. [CrossRef] [PubMed]
24. Balko, J.M.; Giltnane, J.M.; Wang, K.; Schwarz, L.J.; Young, C.D.; Cook, R.S.; Owens, P.; Sanders, M.E.; Kuba, M.G.; Sánchez, V.; et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014, 4, 232–245. [CrossRef] [PubMed]
25. Sflomos, G.; Dormoy, V.; Metsalu, T.; Jeitziner, R.; Battista, L.; Scabia, V.; Raffoul, W.; Delaloye, J.F.; Treboux, A.; Fiche, M.; et al. A preclinical model for ERα-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 2016, 29, 407–422. [CrossRef] [PubMed]
26. Weeber, F.; Salo, N.O.; Krijn, K.D.; Voest, E.E. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. Cell Chem. Biol. 2017, 24, 1093–1100. [CrossRef] [PubMed]
27. Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K.; et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159, 176–187. [CrossRef] [PubMed]
28. Grillet, F.; Bayet, E.; Villeronce, O.; Zappia, L.; Lagerqvist, E.L.; Lunke, S.; Charafe-Jauffret, E.; Pham, K.; Molck, C.; Rolland, N.; et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut 2016, 66, 1802–1810. [CrossRef] [PubMed]
29. Yu, M.; Bardia, A.; Aceto, N.; Bersani, F.; Madden, M.W.; Donaldson, M.C.; Desai, R.; Zhu, H.; Comaills, V.; Zheng, Z. Cancer therapy. Ex Vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345, 216–220. [CrossRef] [PubMed]
30. Baccelli, I.; Schneeweiss, A.; Riethdorf, S.; Stenzinger, A.; Schillert, A.; Vogel, V.; Klein, C.; Saini, M.; Bäuerle, T.; Wallwiener, M.; et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013, 31, 539–544. [CrossRef] [PubMed]
31. Hodgkinson, C.L.; Morrow, C.J.; Li, Y.; Metcalf, R.L.; Rothwell, D.G.; Trapani, F.; Polanski, R.; Burt, D.J.; Simpson, K.L.; Morris, K.; et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat. Med. 2014, 20, 897–903. [CrossRef] [PubMed]
32. Rossi, E.; Rugge, M.; Facchinetti, A.; Pizzi, M.; Nardo, G.; Barbieri, V.; Manicone, M.; De Faveri, S.; Scaini, M.C.; Basso, U.; et al. Retaining the long-survive capacity of circulating tumor cells (CTCs) followed by xeno-transplantation: Not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience 2014, 1, 49–56. [CrossRef] [PubMed]
33. Williams, E.S.; Rodriguez-Bravo, V.; Chippada-Venkata, U.; De Ia Iglesia-Vicente, J.; Gong, Y.; Galsky, M.; Oh, W.; Cordon-Cardo, C.; Domingo-Domenech, J. Generation of prostate cancer patient derived xenograft models from circulating tumor cells. J. Vis. Exp. 2015, 105, 53182. [CrossRef] [PubMed]
34. Joosse, S.A.; Gorges, T.M.; Pantel, K. Biology, detection and clinical implications of circulating tumor cells. EMBO Mol. Med. 2015, 7, 1–11. [CrossRef] [PubMed]
35. Cassidy, J.W.; Caidas, C.; Bruna, A. Maintaining tumor heterogenetity in patient-derived tumor xenographs. Cancer Res. 2015, 75, 2963–2968. [CrossRef] [PubMed]
36. Rygaard, J.; Povlsen, C.O. Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathol. Microbiol. Scand. 1969, 77, 758–760. [CrossRef] [PubMed]
37. Bosma, M.J. B and T cell leakiness in the scid mouse mutant. Immunodefic. Rev. 1992, 3, 261–276. [PubMed]
38. Ito, M.; Hiramatsu, H.; Kobayashi, K.; Suzue, K.; Kawahata, M.; Hioki, K.; Ueyama, Y.; Koyanagi, Y.; Sugamura, K.; Tsuji, K.; et al. NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood 2002, 100, 3175–3182. [CrossRef] [PubMed]
39. Shultz, L.D.; Lyons, B.L.; Burzenski, L.M.; Gott, B.; Chen, X.; Chaleff, S.; Kotb, M.; Gillies, S.D.; King, M.; Mangada, J.; et al. Human lymphoid and myeloid cell development in NOD/LtSz-SCID IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005, 174, 6477–6489. [CrossRef] [PubMed]
40. Priolo, C.; Agostini, M.; Vena, N.; Ligon, A.H.; Fiorentino, M.; Shin, E.; Farsette, A.; Pontecorvi, A.; Sicinska, E.; Loda, M. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am. J. Pathol. 2010, 176, 1901–1913. [CrossRef] [PubMed]
41. Zhang, X.; Claerhout, S.; Prat, A.; Dobrolecki, L.E.; Petrovic, I.; Lai, Q.; Landis, M.D.; Wiechmann, L.; Schiff, R.; Giuliano, M.; et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013, 73, 4885–4897. [CrossRef] [PubMed]
42. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456, 593–598. [CrossRef] [PubMed]
43. Klco, J.M.; Spencer, D.H.; Miller, C.A.; Griffith, M.; Lamprecht, T.L.; O’Laughlin, M.; Fronick, C.; Magrini, V.; Demeter, R.T.; Fulton, R.S.; et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25, 379–392. [CrossRef] [PubMed]
44. Pompili, L.; Porru, M.; Caruso, C.; Biroccio, A.; Leonetti, C. Patient-derived xenografts: A relevant preclinical model for drug development. J. Exp. Clin. Cancer Res. 2016, 35, 189–198. [CrossRef] [PubMed]
45. Ilie, M.; Nunes, M.; Blot, L.; Hofman, V.; Long-Mira, E.; Butori, C.; Selva, E.; Merino-Trigo, A.; Vénissac, N.; Mouroux, J.; et al. Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. Cancer Med. 2015, 4, 201–211. [CrossRef] [PubMed]
46. Kato, C.; Fujii, E.; Chen, Y.J.; Endaya, B.B.; Matsubara, K.; Suzuki, M.; Ohnishi, Y.; Tamaoki, N. Spontaneous thymic lymphomas in the non-obese diabetic/Shi-SCID, IL-2R gamma (null) mouse. Lab. Anim. 2009, 43, 402–404. [CrossRef] [PubMed]
47. Wetterauer, C.; Vlajnic, T.; Schuler, J.; Gsponer, J.R.; Thalmann, G.N.; Cecchini, M.; Schneider, J.; Zellweger, T.; Pueschel, H.; Bachmann, A.; et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate 2015, 75, 585–592. [CrossRef] [PubMed]
48. Staack, A.; Kassis, A.P.; Olshen, A.; Wang, Y.; Wu, D.; Carroll, P.R.; Grossfeld, G.D.; Cunha, G.R.; Hayward, S.W. Quantitation of apoptotic activity following castration in human prostatic tissue in vivo. Prostate 2003, 54, 212–219. [CrossRef] [PubMed]
49. Van Weerden, W.M.; Van Steenbrugge, G.J.; Van Kreuningen, A.; Moerings, E.P.; De Jong, F.H.; Schröde, F.H. Assessment of the Critical Level of Androgen for Growth Response of Transplantable Human Prostatic Carcinoma (PC-82) in Nude Mice. J. Urol. 1991, 145, 631–634. [CrossRef]
50. Wang, Y.; Wang, J.X.; Xue, H.; Lin, D.; Dong, X.; Gout, P.W.; Gao, X.; Pang, J. Subrenal capsule grafting technology in human cancer modeling and translational cancer research. Differentiation 2016, 91, 15–19. [CrossRef] [PubMed]
51. DeRose, Y.S.; Wang, G.; Lin, Y.C.; Bernard, P.S.; Buys, S.S.; Ebbert, M.T.; Factor, R.; Matsen, C.; Milash, B.A.; Nelson, E.; et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17, 1514–1520. [CrossRef] [PubMed]
52. Dotto, G.P. Multifocal epithelial tumors and field cancerization: Stroma as a primary determinant. J. Clin. Investig. 2014, 124, 1446–1453. [CrossRef] [PubMed]
53. Kraaij, R.; van Weerden, W.M.; de Ridder, C.M.; Gussenhoven, E.J.; Honkoop, J.; Nasu, Y.; Bangma, C. HValidation of transrectal ultrasonographic volumetry for orthotopic prostate tumours in mice. Lab. Anim. 2002, 36, 165–172. [CrossRef] [PubMed]
54. Fu, X.Y.; Theodorescu, D.; Kerbel, R.S.; Hoffman, R.M. Extensive multi-organ metastasis following orthotopic onplantation of histologically-intact human bladder carcinoma tissue in nude mice. Int. J. Cancer 1991, 49, 938–939. [CrossRef] [PubMed]
55. Fu, X.; Guadagni, F.; Hoffman, R.M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 1992, 89, 5645–5649. [CrossRef] [PubMed]
56. Garrido-Laguna, I.; Uson, M.; Rajeshkumar, N.V.; Tan, A.C.; de Oliveira, E.; Karikari, C.; Villaroel, M.C.; Salomon, A.; Taylor, G.; Sharma, R.; et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 2011, 17, 5793–5800. [CrossRef] [PubMed]
57. Hoffman, R.M. Patient-Derived Mouse Models of Cancer. Nat. Rev. Cancer 2015, 15, 451–452. [CrossRef] [PubMed]
58. Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. Nature 2011, 480, 480–489. [CrossRef] [PubMed]
59. Farkona, S.; Diamandis, E.P.; Blasutig, I.M. Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 2016, 14, 73–79. [CrossRef] [PubMed]
60. Siolas, D.; Hannon, G.J. Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res. 2013, 73, 5315–5319. [CrossRef] [PubMed]
61. Talmadge, J.E.; Singh, R.K.; Fidler, I.J; Raz, A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am. J. Pathol. 2007, 170, 793–804. [CrossRef] [PubMed]
62. Shultz, L.D.; Brehm, M.A.; Garcia-Martinez, J.V.; Greiner, D.L. Humanized mice for immune system investigation: Progress, promise and challenges. Nat. Rev. Immunol. 2012, 12, 786–798. [CrossRef] [PubMed]
63. Rongvaux, A.; Willinger, T.; Martinek, J.; Strowig, T.; Gearty, S.V.; Teichmann, L.L.; Saito, Y.; Marches, F.; Halene, S.; Palucka, A.K.; et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 2014, 32, 362–372. [CrossRef] [PubMed]
64. Reyal, F.; Guyader, C.; Decraene, C.; Lucchesi, C.; Auger, N.; Assayag, F.; De Plater, L.; Gentien, D.; Poupon, M.F.; Cottu, P.; et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012, 14, R11. [CrossRef] [PubMed]
65. Braekeveldt, N.; Wigerup, C.; Tadeo, I.; Beckman, S.; Sanden, C.; Jonsson, J.; Erjefält, J.S.; Berbegall, A.P.; Börjesson, A.; Backman, T.; et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 2016, 375, 384–389. [CrossRef] [PubMed]
66. Utama, F.E.; Tran, T.H.; Ryder, A.; LeBaron, M.J.; Parlow, A.F.; Rui, H. Insensitivity of human prolactin receptors to nonhuman prolactins: Relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 2009, 150, 1782–1790. [CrossRef] [PubMed]
67. Dong, Z.; Imai, A.; Krishnamurthy, S.; Zhang, Z.; Zeitlin, B.D.; Nör, J.E. Xenograft Tumors Vascularized with Murine Blood Vessels May Overestimate the Effect of Anti-Tumor Drugs: A Pilot Study. PLoS ONE 2013, 8, e84236. [CrossRef] [PubMed]
68. Visonneau, S.; Cesano, A.; Torosian, M.H.; Miller, E.J.; Santoli, D. Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am. J. Pathol. 1998, 152, 1299–1311. [PubMed]
69. Fu, S.; Zhao, J.; Bai, H.; Duan, J.; Wang, Z.; An, T.; Wang, J. High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. Thorac. Cancer 2016, 7, 100–110. [CrossRef] [PubMed]
70. Sausville, E.A.; Burger, A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66, 3351–3354. [CrossRef] [PubMed]
71. Daniel, V.C.; Marchionni, L.; Hierman, J.S.; Rhodes, J.T.; Devereux, W.L.; Rudin, C.M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C.D.; et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009, 69, 3364–3373. [CrossRef] [PubMed]
72. Walters, D.M.; Stokes, J.B.; Adair, S.J.; Stelow, E.B.; Borgman, C.A.; Lowrey, B.T.; Xin, W.; Blais, E.M.; Lee, J.K.; Papin, J.A.; et al. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS ONE 2013, 8, e77065. [CrossRef] [PubMed]
73. Petrillo, L.A.; Wolf, D.M.; Kapoun, A.M.; Wang, N.J.; Barczak, A.; Xiao, Y.; Korkaya, H.; Baehner, F.; Lewicki, J.; Wicha, M.; et al. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res. Treat. 2012, 135, 913–922. [CrossRef] [PubMed]
74. Povlsen, C.O.; Visfeldt, J.; Rygaard, J.; Jensen, G. Growth patterns and chromosome constitutions of human malignant tumours after long-term serial transplantation in nude mice. Acta Pathol. Microbiol. Scand. A Pathol. 1975, 83, 709–716. [CrossRef]
75. Zhao, X.; Liu, Z.; Yu, L.; Zhang, Y.; Baxter, P.; Voicu, H.; Gurusiddappa, S.; Luan, J.; Su, J.M.; Leung, H.C.; et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro-Oncology 2012, 14, 574–583. [CrossRef] [PubMed]
76. Goodspeed, A.; Heiser, L.A.; Gray, J.W.; Costello, J.C. Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol. Cancer Res. 2016, 14, 1–13. [CrossRef] [PubMed]
77. Boehm, J.S.; Golub, T.R. An ecosystem of cancer cell line factories to support a cancer dependency map. Nat. Rev. 2015, 16, 373–374. [CrossRef] [PubMed]
78. Greenman, J. Looking to the future of organs-on-chip. Future Sci. OA 2017, 3, 205. [CrossRef] [PubMed]
79. Van Weerden, W.M.; de Ridder, C.M.; Verdaasdonk, C.L.; Romijn, J.C.; van der Kwast, T.H.; Schröder, F.H.; van Steenbrugge, G.J. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 1996, 149, 1055–1062. [PubMed]
80. Eirew, P.; Steif, A.; Khattra, J.; Ha, G.; Yap, D.; Farahani, H.; Gelmon, K.; Chia, S.; Mar, C.; Wan, A.; et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 2015, 518, 422. [CrossRef] [PubMed]
81. Ben-David, U.; Gavin, H.; Yuen-Yi, T.; Greenwald, N.F.; Oh, C.; Shih, J.; McFarland, J.M.; Wong, B.; Boehm, J.S.; Beroukhim, R.; et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 2017, 49, 1567–1575. [CrossRef] [PubMed]
82. Lodhia, K.A.; Hadley, A.M.; Haluska, P.; Scott, C.L. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim. Biophys. Acta 2015, 1855, 223–234. [CrossRef] [PubMed]
83. Weroha, S.J.; Becker, M.A.; Enderica-Gonzalez, S.; Harrington, S.C.; Oberg, A.L.; Maurer, M.J.; Perkins, S.E.; AlHilli, M.; Butler, K.A.; McKinstry, S.; et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 2014, 20, 1288–1297. [CrossRef] [PubMed]
84. Kemper, K.; Krijgsman, O.; Cornelissen-Steijger, P.; Shahrabi, A.; Weeber, F.; Song, J.Y.; Kuilman, T.; Vis, D.J.; Wessels, L.F.; Voest, E.E.; et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 2015, 7, 1104–1118. [CrossRef] [PubMed]
85. Williams, J.A. Patient-Derived Xenografts as cancer Models for Preclinical Screening. In Patient-Derived Xenograft Models of Human Cancer; Springer International Publishing: Berlin, Germany, 2017; pp. 141–154.
86. Migliardi, G.; Sassi, F.; Torti, D.; Galimi, F.; Zanella, E.R.; Buscarino, M.; Ribero, D.; Muratore, A.; Massucco, P.; Pisacane, A.; et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin. Cancer Res. 2012, 18, 2515–2525. [CrossRef] [PubMed]
87. Bertotti, A.; Migliardi, G.; Galimi, F.; Sassi, F.; Torti, D.; Isella, C.; Corà, D.; Di Nicolantonio, F.; Buscarino, M.; Petti, C.; et al. A molecularly annotated platform of patient-dervied xenografts (“xenopatients”) identifies HER2 as an effective therpeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1, 508–523. [CrossRef] [PubMed]
88. Murphy, B.; Yin, H.; Maris, J.M.; Kolb, E.A.; Gorlick, R.; Reynolds, C.P.; Kang, M.H.; Keir, S.T.; Kurmasheva, R.T.; Dvorchik, I.; et al. Evaluation of alternative in vivo drug screen methodology: A single mouse analysis. Cancer Res. 2016, 76, 5798–5809. [CrossRef] [PubMed]
89. Yao, Y.M.; Donoho, G.P.; Iversen, P.W.; Zhang, Y.; Van Horn, R.D.; Forest, A.; Novosiadly, R.D.; Webster, Y.W.; Ebert, P.; Bray, S.; et al. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. Clin. Cancer Res. 2017, 23, 5547–5560. [CrossRef] [PubMed]
90. Arrowsmith, J.; Miller, P. Trial watch: Phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 2013, 12, 569. [CrossRef] [PubMed]
91. Arrowsmith, J. Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov. 2011, 10, 328–329. [CrossRef] [PubMed]
92. Julien, S.; Merino-Trigo, A.; Lacroix, L.; Pocard, M.; Goéré, D.; Mariani, P.; Landron, S.; Bigot, L.; Nemati, F.; Dartigues, P.; et al. Characterization of a large panel of patient derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 2012, 19, 2929–2940. [CrossRef] [PubMed]
93. Lièvre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Côté, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66, 3992–3995. [CrossRef] [PubMed]
94. Bialucha, C.; Collins, S.; Li, X.; Saxena, P.; Zhang, X.; Duerr, C.; Lafont, B.; Prieur, P.; Shim, Y.; Mosher, R.; et al. Discovery and optimization of HKT288, a cadherin-6 targeting ADC for the treatment of ovarian and renal cancer. Cancer Discov. 2017, 7, 1030–1045. [CrossRef] [PubMed]
95. Collins, S.; Bialucha, C.U.; Williams, J.A.; Gao, H. Utilizing panels of patient derived xenografts to aid the development of antibody. Mol. Cell. Oncol. 2017, 5, e1394422. [CrossRef] [PubMed]
96. Wang, H.; Nicolay, B.; Chick, J.; Gao, X.; Geng, Y.; Ren, H.; Gao, H.; Williams, J.A.; Sicinska, E.; Roberts, T.; et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 2017, 546, 426–430. [CrossRef] [PubMed]
97. Palmer, A.C.; Sorger, P.K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 2017, 171, 1678–1691. [CrossRef] [PubMed]
98. Van Soest, R.J.; de Morrée, E.S.; Kweldam, C.F.; de Ridder, C.M.A.; Wiemer, E.A.C.; Mathijssen, R.H.J.; de Wit, R.; van Weerden, W.M. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur. Urol. 2015, 67, 981–985. [CrossRef] [PubMed]
99. Marques, R.B.; Aghai, A.; de Ridder, C.M.A.; Stuurman, D.; Hoeben, S.; Boer, A.; Ellston, R.P.; Barry, S.T.; Davies, B.R.; Trapman, J.; et al. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. J. Eur. Urol. 2015, 67, 1177–1185. [CrossRef] [PubMed]